2 year old Caucasian male
Switched to ALTUVIIIO: July 2023
Noah, who has severe hemophilia A, presented for a comprehensive care visit. Noah’s mother wanted to feel confident in his bleed protection while he’s at daycare and she’s at work.
Patient Information
Noah’s Path to High Sustained Factor Replacement Therapy, ALTUVIIIO
Diagnosis
Birth: Diagnosed with severe hemophilia A following uncontrolled bleeding from heel stick and circumcision
- Was found to have a de novo mutation with no family history of hemophilia
After diagnosis
6 months old: Noah was initiated on extended half-life therapy and standard half-life therapy on demand.
2 years old: Noah is becoming increasingly physically active and is attending daycare.
Before ALTUVIIIO
- Noah presented for a comprehensive care visit
Considering the switch
Provider and Noah’s mother discussed concerns about Noah’s:
- Increasing physical activity
- Need for proven bleed protection
Provider and Noah’s mother determined ALTUVIIIO was the optimal therapeutic choice to:
- Provide bleed protection for Noah1
After ALTUVIIIO
Switched to ALTUVIIIO: July 2023
- Since switching to ALTUVIIIO, Noah has normal to near-normal Factor VIII levels (>40%) for ~3 days of the week. He has experienced 0 spontaneous bleeds and his mother now feels confident in his bleed protection1
Do you have patients like Noah?
If so, it may be worth it to consider the following:
How good is good enough?
Would you consider a patient like Noah to be doing okay on their current treatment?
Choosing the right treatment
How would you discuss switching to a more appropriate treatment option, like ALTUVIIIO, with patients like Noah?
Unlocking high sustained factor levels
Do you think high sustained factor levels and once-weekly dosing with ALTUVIIIO1 could benefit your patients like Noah?
EHL=extended half-life; FVIII=Factor VIII; IU=international unit; IV=intravenous; SHL=standard half-life; Wt=weight.
Other ALTUVIIIO patients who made the switch!
Meet Peter
A 32 year old reverend with severe hemophilia A previously on prophylaxis therapy.
Meet Otis
A 43 year old who works loading trucks and previously treated his moderate hemophilia A with an on-demand therapy.
Indication
Reference: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA.
